From BBC Health - June 05, 2006 08:54
Use of a new class of breast cancer drug has the potential to save 1,000 lives a year in the UK, trials suggest.
Use of a new class of breast cancer drug has the potential to save 1,000 lives a year in the UK, trials suggest.
Aromasin cut the risk of death among postmenopausal women with hormone-sensitive primary breast cancer by 17% compared with standard therapy.
Instead of five years of the drug tamoxifen, the women were switched to Aromasin after two to three years.
Details of the UK-led study were presented to an American Society of Clinical Oncology conference.